India’s Bharat COVID-19 Vaccine Claims to be 93 Percent Effective Against Severe Symptoms

Liputan6.com, Delhi – Phase III trial vaksin COVID-19 Bharat Biotech India claimed to be 93.4 percent effective against COVID-19 severe symptoms, according to the company on Saturday July 3, 2021, a finding that could increase the acceptance of Covaxin in the community.

The data showed a 65.2 percent protection against the Delta variant of COVID, which first appeared in India, which caused a spike in infections from April to May and the highest daily death toll in the world.

The domestically made vaccine also showed 77.8 percent efficacy against COVID-19 symptoms in the trial.

Last month the manufacturer AstraZeneca also claimed that its vaccine was effective against the Delta and Kappa variants of COVID, citing a study.

India has provided AstraZeneca’s COVID-19 vaccine, which is produced domestically by the Serum Institute of India. It plans to increase its monthly production starting in July, to almost 100 million doses.

Bharat Biotech now estimates it can produce 23 million doses per month.

The phase III trial data comes as Ocugen, which works with Bharat Biotech to develop Covacsin for the US market, prepares to apply for full US approval.

India, which has confirmed 30.45 million infections, is the world’s second worst-hit country after the US, with 33 million infections. The total number of COVID-19 deaths in Bollywood has now crossed the 400,000 mark.

–